TITUSVILLE, N.J., Sept. 24, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. announced the results of a first-of-its-kind study, The Impact of JANSSEN® CONNECT® Injection Centers on Adherence to an Atypical Long-Acting Injectable Antipsychotic among Patients with Schizophrenia Enrolled in a Support Program. Results of this retrospective, observational research were presented at the 27th Annual U.S. Psychiatric and Mental Health Congress Conference and Exhibition in Orlando on Sept. 20-23. The study showed that JANSSEN® CONNECT® patients who received their Janssen long-acting treatment (JLAT) at an injection center, typically a pharmacy, and remained in the program...
↧